MPN Watch

Dossier web review 03-aug-2026

Emerging agents and regimens for myeloproliferative neoplasms: updates from ASH 2025 Annual Meeting

Key claim: ASH 2025 updates highlight emerging MPN agents and regimens intended to address infrequent molecular remissions and treatment-limiting cytopenias of current therapies.

Abstract

Expert commentary review discussing emerging agents and regimens for MPN presented at ASH 2025, addressing limitations of current therapies including infrequent molecular remissions and treatment-limiting cytopenias.

Why this matters

ASH 2025 updates highlight emerging MPN agents and regimens intended to address infrequent molecular remissions and treatment-limiting cytopenias of current therapies.

Source

Link

Briefing card

Emerging agents and regimens for myeloproliferative neoplasms: updates from ASH 2025 Annual Meeting
Stage: review · web · 03-aug-2026

ASH 2025 updates highlight emerging MPN agents and regimens intended to address infrequent molecular remissions and treatment-limiting cytopenias of current therapies.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: url:https://pubmed.ncbi.nlm.nih.gov/42547880/

Ask about this finding

Replies are grounded in the abstract and metadata above. The model will quote directly when possible and say so if a question isn't covered.

Subscribe: calendar of upcoming dates · deadlines feed · all new records · Help

build build 612 · 69ce4cf-dirty · 2026-11-11